Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Ticpot** is an approved injectable fixed-dose antibacterial product from Unifaith Biotech containing **ticarcillin** and **clavulanic acid**. Ticarcillin is a semisynthetic carboxypenicillin that kills susceptible bacteria by inhibiting penicillin-binding proteins and bacterial peptidoglycan cell-wall synthesis. Clavulanic acid is a beta-lactamase inhibitor that protects ticarcillin from enzymatic degradation, extending activity against susceptible beta-lactamase-producing organisms. Ticpot is supplied as a 3 g ticarcillin plus 100 mg clavulanic acid injection for serious bacterial infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ticarcillin + clavulanic acid.